Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiki Takamatsu

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 18, 2023
[Widely Applicable Strategies Against Cancer, Type II Diabetes, and Neurodegenerative Diseases by Means of Rationally Designed Anti-Amyloidogenic Molecules]Yoshiki Takamatsu, Makoto Hashimoto
Brain Research|May 14, 2003
Immunohistochemical study of Ca2+/calmodulin-dependent protein kinase II in the Drosophila brain using a specific monoclonal antibodyYoshiki Takamatsu, Yasuko Kishimoto, Shunji Ohsako
Trends in Cancer|May 11, 2020
Amyloid Evolvability and CancerYoshiki Takamatsu, Gilbert Ho, Makoto Hashimoto
Biochemical and Biophysical Research Communications|June 21, 2014
Role of genomics in translational research for Parkinson's diseaseKazunari Sekiyama, Yoshiki Takamatsu, Masaaki Waragai, et al.
Biomolecules|May 22, 2015
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related SynucleinopathiesAkio Sekigawa, Yoshiki Takamatsu, Kazunari Sekiyama, et al.
Neoplasia (New York, N.Y.)|December 14, 2020
Adiponectin paradox as a therapeutic target of the cancer evolvability in agingYoshiki Takamatsu, Gilbert Ho, Ryoko Wada, et al.
Parkinson'S Disease|December 3, 2021
Therapeutic Potential of <i>α</i>-Synuclein Evolvability for Autosomal Recessive Parkinson's DiseaseJianshe Wei, Gilbert Ho, Yoshiki Takamatsu, et al.
International Journal of Molecular Sciences|October 31, 2012
Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathiesMasayo Fujita, Akio Sekigawa, Kazunari Sekiyama, et al.
International Journal of Molecular Sciences|December 15, 2010
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's DiseaseMasaaki Waragai, Kazunari Sekiyama, Akio Sekigawa, et al.
International Journal of Molecular Sciences|April 25, 2020
Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-SynucleinMasayo Fujita, Gilbert Ho, Yoshiki Takamatsu, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 18, 2023
[Widely Applicable Strategies Against Cancer, Type II Diabetes, and Neurodegenerative Diseases by Means of Rationally Designed Anti-Amyloidogenic Molecules]Yoshiki Takamatsu, Makoto Hashimoto
Brain Research|May 14, 2003
Immunohistochemical study of Ca2+/calmodulin-dependent protein kinase II in the Drosophila brain using a specific monoclonal antibodyYoshiki Takamatsu, Yasuko Kishimoto, Shunji Ohsako
Trends in Cancer|May 11, 2020
Amyloid Evolvability and CancerYoshiki Takamatsu, Gilbert Ho, Makoto Hashimoto
Biochemical and Biophysical Research Communications|June 21, 2014
Role of genomics in translational research for Parkinson's diseaseKazunari Sekiyama, Yoshiki Takamatsu, Masaaki Waragai, et al.
Biomolecules|May 22, 2015
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related SynucleinopathiesAkio Sekigawa, Yoshiki Takamatsu, Kazunari Sekiyama, et al.
Neoplasia (New York, N.Y.)|December 14, 2020
Adiponectin paradox as a therapeutic target of the cancer evolvability in agingYoshiki Takamatsu, Gilbert Ho, Ryoko Wada, et al.
Parkinson'S Disease|December 3, 2021
Therapeutic Potential of <i>α</i>-Synuclein Evolvability for Autosomal Recessive Parkinson's DiseaseJianshe Wei, Gilbert Ho, Yoshiki Takamatsu, et al.
International Journal of Molecular Sciences|October 31, 2012
Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathiesMasayo Fujita, Akio Sekigawa, Kazunari Sekiyama, et al.
International Journal of Molecular Sciences|December 15, 2010
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's DiseaseMasaaki Waragai, Kazunari Sekiyama, Akio Sekigawa, et al.
International Journal of Molecular Sciences|April 25, 2020
Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-SynucleinMasayo Fujita, Gilbert Ho, Yoshiki Takamatsu, et al.
Pageof 4